These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33248483)

  • 1. First-line treatment for type 2 diabetes: is it too early to abandon metformin?
    Zaccardi F; Khunti K; Marx N; Davies MJ
    Lancet; 2020 Nov; 396(10264):1705-1707. PubMed ID: 33248483
    [No Abstract]   [Full Text] [Related]  

  • 2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
    Niessner A; Tamargo J; Koller L; Saely CH; Schmidt TA; Savarese G; Wassmann S; Rosano G; Ceconi C; Torp-Pedersen C; Kaski JC; Kjeldsen KP; Agewall S; Walther T; Drexel H; Lewis BS
    Eur Heart J; 2018 Jun; 39(24):2274-2281. PubMed ID: 29126266
    [No Abstract]   [Full Text] [Related]  

  • 5. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
    Qiu M; Zhou X; Zhang M
    Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical decisions. Management of type 2 diabetes--polling results.
    Schulte JM; Rothaus CS; Adler JN
    N Engl J Med; 2014 Jan; 370(1):e2. PubMed ID: 24382086
    [No Abstract]   [Full Text] [Related]  

  • 8. Incorporating New Medications in Diabetes Care.
    Comi RJ
    Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
    [No Abstract]   [Full Text] [Related]  

  • 9. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
    Paquot N; Scheen AJ
    Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].
    Álvarez-Guisasola F; Orozco-Beltrán D; Cebrián-Cuenca AM; Ruiz Quintero MA; Angullo Martínez E; Ávila Lachica L; Ortega Millán C; Caride Miana E; Navarro-Pérez J; Sagredo Perez J; Barrot de la Puente J; Cos Claramunt FX
    Aten Primaria; 2019; 51(7):442-451. PubMed ID: 31320123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical decisions. Glycemic management in a patient with type 2 diabetes.
    Hirsch IB; Molitch ME
    N Engl J Med; 2013 Oct; 369(14):1370-2. PubMed ID: 24088099
    [No Abstract]   [Full Text] [Related]  

  • 12. Is an SGLT2 inhibitor right for your patient with type 2 diabetes?
    Lisenby KM; Meyer A; Slater NA
    J Fam Pract; 2016 Sep; 65(9):587-93. PubMed ID: 27672684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 14. Determining When to Recommend Glucose-Lowering Drugs That Reduce Cardiovascular Risk.
    Robertson S
    Am Fam Physician; 2022 Jan; 105(1):10-12. PubMed ID: 35029936
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 18. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
    Bagepally BS; Gurav YK; Anothaisintawee T; Youngkong S; Chaikledkaew U; Thakkinstian A
    Value Health; 2019 Dec; 22(12):1458-1469. PubMed ID: 31806203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.